Professor Ken Kato gave us a talk about longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.

Video: https://congressreport.eu/scientific-contents/standalonecontent:first-line-pembrolizumab-plus-chemotherapy-versus-chemotherapy-advanced-esophageal-cancer

Professor Matthew R. Zibelman gave us updates in bladder or urothelial cancers after the recent ASCO GU symposium 2022 from San Francisco.

Video: https://congressreport.eu/scientific-contents/standalonecontent:state-art-treatment-bladder-cancer

Professor Piotr Ponikowski gave us a talk about iron deficiency in heart failure in the context of prevalence, clinical significance and potential therapeutic consequences.

Video: https://congressreport.eu/scientific-contents/standalonecontent:treatment-iron-deficiency-acute-and-chronic-heart-failure

Professor Hubert Seggewiss gave us a talk about alcohol septal ablation in hypertrophic cardiomyopathy.

Video: https://congressreport.eu/scientific-contents/standalonecontent:alcohol-septal-ablation-hypertrophic-cardiomyopathy-past-and-future

Professor Petar Seferovic gave us a talk on the new drugs and strategies regarding the heart failure. He spoke about SGLT2 inhibitors too, which are one of the most important breaktroughs in the treatemnt of heart failure.

Video: https://congressreport.eu/scientific-contents/standalonecontent:use-sglt2-inhibitors-prevention-and-treatment-heart-failure

Professor Iacopo Olivotto gave us a talk on new developments about myosin inhibitors and that use in hypertrophic cardiomyopathy. Last year they presented EXPLORER-HCM study, since then several things happened.

Video: https://congressreport.eu/scientific-contents/standalonecontent:direct-myosin-inhibitors-hypertrophic-cardiomyopathy-new-era

Diagnostic delays in pulmonary arterial hypertension are related to increased morbidity and mortality. The risk of a delayed, or even a missed, diagnosis is high as the conditions are rare. The aim of the study was to describe patients’ and spouses’ experiences of the journey from the first symptom to an established diagnosis.

The study: https://journals.sagepub.com/doi/10.1177/21501327211029241

Video: https://congressreport.eu/scientific-contents/standalonecontent:diagnostic-delay-pulmonary-arterial-hypertension

In this review, Dr. Babak Dehestani aim to explain the mechanism of action of Liraglutide, its pharmacokinetic properties, its clinical impact on obesity and its safety and tolerability.

Video: https://congressreport.eu/scientific-contents/standalonecontent:clinical-impact-liraglutide-treatment-obesity-2

Professor Michael Camilleri gave us a review on the topic.

Video: https://congressreport.eu/scientific-contents/standalonecontent:association-glp-1-analogs-and-agonists-administered-obesity-weight-loss-and-adverse-events

Professor Andrzej Jakubowiak speak about the novelties and state of the art treatment presented at ASH 2021.

Video: https://congressreport.eu/scientific-contents/interview:novelties-treatment-multiple-myeloma-2021